Sue Desmond-Hell­mann joins the mar­quee crowd of bio­phar­ma ex­perts at GV boot­ing up a new gen­er­a­tion of drug hunters

Sue Desmond-Hell­mann has start­ed the next chap­ter of her sto­ried ca­reer in bio­phar­ma.

GV — the ven­ture group for­mer­ly known as Google Ven­tures — has opened its doors to add her to their list of mar­quee drug ex­perts.

David Schenkein, who made the leap to GV af­ter start­ing from scratch to build Agios in­to a com­mer­cial-stage biotech in 10 years, of­fered his thumbs-up on Twit­ter af­ter GV put out the word on­line that Desmond-Hell­mann would be join­ing them as a se­nior ad­vis­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER